ArticleFrontiers in microbiology2022
Characterization of Metronidazole-Resistant
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- A high-confidence inventory of the proteins in the mitochondrion-related organelle of Giardia.Current biology : CB · 2026Article
- Covalent Inhibitors in Antimicrobial Drug Development-Beyond β-Lactams.Molecules (Basel, Switzerland) · 2026Review
- Omeprazole as a Novel Treatment Option for Giardiasis in Cats.Veterinary medicine and science · 2026Article
- Review
- mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review.Journal of nanobiotechnology · 2025Review
- Genotype-Specific Small EVs Released by Giardia lamblia Act as Mediators of Phenotypic Adaptation Under Metronidazole-Induced Stress.Journal of extracellular vesicles · 2025Article
- Identifying Molecular Changes inDiagnostics (Basel, Switzerland) · 2025Article
- Human Giardiasis in Ghana - A Scoping Review of Studies From 2004 to 2024.Health science reports · 2025Article
- Implementation of real-time PCR assays for diagnosing intestinal protozoa infections.Parasitology research · 2025Article
- Comprehensive analysis of flavohemoprotein copy number variation in Giardia intestinalis: exploring links to metronidazole resistance.Parasites & vectors · 2024Article
- Harnessing the power of new genetic tools to illuminate Giardia biology and pathogenesis.Genetics · 2024Review
- Assessment of Drug Activities againstPathogens (Basel, Switzerland) · 2024Article
- Development of New PCR Protocols to Detect Genetic Diversity in the Metronidazole Metabolism Genes in Susceptible and Refractory Clinical Samples of Giardia duodenalis.Acta parasitologica · 2024Article
- Rosmarinic Acid Present inPlants (Basel, Switzerland) · 2024Article
- Antibacterial Activities of Ag/Cellulose Nanocomposites Derived from Marine Environment Algae against Bacterial Tooth Decay.Microorganisms · 2023Article
- Spliceosomal introns in the diplomonad parasiteMicrobial genomics · 2023Article
- Prevalence of Intestinal Parasitic Infections, Genotypes, and Drug Susceptibility ofTropical medicine and infectious disease · 2023Article
- Review
- Unusual Cell Structures and Organelles inMicroorganisms · 2022Review
- A chromosome-scale reference genome for Spironucleus salmonicida.Scientific data · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Metronidazole (MTZ) is a clinically important antimicrobial agent that is active against both bacterial and protozoan organisms. MTZ has been used extensively for more than 60 years and until now resistance has been rare. However, a recent and dramatic increase in the number of MTZ resistant bacteria and protozoa is of great concern since there are few alternative drugs with a similarly broad activity spectrum. To identify key factors and mechanisms underlying MTZ resistance, we utilized the protozoan parasite
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.